THERAPEUTIC HOTLINE: Infliximab for treatment of resistant pyoderma gangrenosum associated with ulcerative colitis and psoriasis. A case report

Baglieri, Francesco; Scuderi, G

doi:10.1111/j.1529-8019.2010.01357.x

Cited by 14 publications

(33 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A positive history of recent trauma was reported in seven cases . Only one case had systemic signs of infection with PG onset and responded clinically to antibiotics.…”

Section: Resultsmentioning

confidence: 97%

See 1 more Smart Citation

Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy

Agarwal

Andrews

2013

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…A positive history of recent trauma was reported in seven cases . Only one case had systemic signs of infection with PG onset and responded clinically to antibiotics.…”

Section: Resultsmentioning

confidence: 97%

“…Ten required a second‐line therapy, with nine responding. Of the nine, six had infliximab . Of the other three, two required the addition of topical tacrolimus or mesalazine to oral steroids.…”

Section: Resultsmentioning

confidence: 99%

Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy

Agarwal

Andrews

2013

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Vulgaris psoriasis associated to pyoderma gangrenosum was already described [3,10,11]. Today, as recommended by JH Saurat, the pustular form of psoriasis with pyoderma gangrenosum get into the concept of neutrophilic dermatosis [12].…”

Section: Discussionmentioning

confidence: 96%

“…As for, pyoderma gangrenosum, it can be idiopathic or associated with systemic diseases [2]. The association of these two pathologies is known and includes varies and complex mechanisms [3][4][5]. Psoriasis can be presented in pustular features, and associated with a pyoderma gangrenosum.…”

Section: Introductionmentioning

confidence: 99%

A Pustular Psoriasis of the Face associated with a Perianal Pyoderma Gangrenosum: Same Nosologic Entity?

Alexandre¹

2014

J Clin Exp Dermatol Res

View full text Add to dashboard Cite

Psoriasis can have a pustular feature. When it is associated with a pyoderma gangrenosum, it leads to a nosologic problem. Is it the same entity, neutrophilic dermatosis with different clinical manifestations? Here we report the first clinical case of pustular psoriasis of the face associated with perianal pyoderma gangrenosum. This case comes out with these rare locations of the two diseases, responsible for unclear diagnosis. We highlight the importance of biological examinations, to eliminated the others diseases and the key role of histopatholigical examination into the positive diagnosis. It doesn't to be save up in our context and it have to be done when the treatment failed. The follow up of these two diseases was successful under corticosteroid therapy.

show abstract

“…16,18,22,28,32 In our patient, infliximab was a rapidly effective treatment of PG associated with UC, both of which have been resistant to steroid therapy. This case report supports the use of infliximab as an alternative therapy for PG associated with UC and oral involvement when conventional treatment is ineffective.…”

Section: Resultsmentioning

confidence: 99%

Disseminated refractory pyoderma gangraenosum during an ulcerative colitis flare. Treatment with infliximab.

Zampeli¹,

Lippert²,

Nikolakis³

et al. 2015

J Dermatol Case Rep

View full text Add to dashboard Cite

Background: Pyoderma gangraenosum is an immune-mediated, inflammatory, neutrophilic dermatosis of unknown etiology, which represents one of the extraintestinal manifestations of inflammatory bowel disease. It is a rare disease that occurs in less than 1% of patients with inflammatory bowel disease and with the same ratio in patients with Crohn's disease and ulcerative colitis. Main observations:A 36-year-old woman was diagnosed with ulcerative colitis 6 years before admission to our dermatology department with an acute disseminated pyoderma gangraenosum with mucosal involvement, during a flare of ulcerative colitis. Disease progression was interrupted by intravenous administration of the tumor necrosis factor-α inhibitor infliximab at 5mg/kg at weeks 0, 2, and 6 (1st cycle) and every 8 weeks thereafter. Improvement of intestinal, skin and oral manifestations was evident already after the 1st cycle of treatment and has been maintained since (at least 16 months). Conclusions:This case report is one of very few on disseminated pyoderma gangraenosum with oral involvement complicating ulcerative colitis, where infliximab was shown to have a rapid efficacy on skin, mucosal and bowel symptoms. (J Dermatol Case Rep. 2015; 9(3): 62-66) Disseminated refractory pyoderma gangraenosum during an ulcerative colitis flare. Treatment with infliximab. IntroductionPyoderma gangraenosum (PG) is a severe ulcerating, primarily sterile, neutrophilic dermatosis. It can occur in association with systemic diseases in adults, the most common of which is ulcerative colitis (UC). 1 PG has been reported in 1-10% of patients with UC, 2 affecting equally men and women with a peak age incidence between 25 and 54 years. Approximately 50-78% of patients with PG have an underlying systemic disease 3 such as inflammatory bowel disease (IBD), myeloproliferative and rheumatological diseases. 4 PG has been reported to occur before, during, after or even independently of the onset of an underlying IBD. 5Four clinical and histological variants of PG have been described: ulcerative, pustular, bullous, and vegetative. 4 We present here a female patient with severe, disseminated PG, refractory to conventional treatment, during a clinical flare of a previously diagnosed UC. Both entities responded to infliximab, a chimeric monoclonal antibody that inhibits tumor necrosis factor-α (TNF-α). Case report Medical HistoryA 36-year-old female was diagnosed with UC in 2005. The leading symptom was bloody diarrhea. Under treatment with mesalazine, remission was maintained for nearly 5 years. In October 2010, the patient relapsed with bloody diarrhea (at DOI: http://dx.doi.org/10.3315/jdcr.2015DOI: http://dx.doi.org/10.3315/jdcr. .1206 62 least eight stools per day), fever and diffuse abdominal pain with increasing severity of the symptoms. She was admitted to an internal medicine department, where she was treated with antibiotics (levofloxacin and metronidazol), mesalazine, sulfasalazin and low-dose corticosteroids (20 mg prednisone daily). After tw...

show abstract

THERAPEUTIC HOTLINE: Infliximab for treatment of resistant pyoderma gangrenosum associated with ulcerative colitis and psoriasis. A case report

Cited by 14 publications

References 19 publications

Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy

Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy

A Pustular Psoriasis of the Face associated with a Perianal Pyoderma Gangrenosum: Same Nosologic Entity?

Disseminated refractory pyoderma gangraenosum during an ulcerative colitis flare. Treatment with infliximab.

Contact Info

Product

Resources

About